[Preventive treatment of prolongation of the QT interval]

Jarosław Szponar1, Karolina Zapalska-Pozarowska, Elzbieta Szponar

  • 1Samodzielny Publiczny Szpital Wojewódzki im. Jana Bozego w Lublinie, Regionalny Ośrodek Toksykologii Klinicznej. szponar.jarek@gmail.com

Przeglad Lekarski
|December 19, 2012
PubMed

Insights

Prolongation of the QT interval, a measure of heart rhythm, indicates poor prognosis in various heart conditions. Understanding its causes and accurate measurement is crucial for managing long QT syndrome and preventing adverse outcomes.

Area of Science:

  • Cardiology
  • Clinical Electrophysiology

Context:

  • QT interval prolongation is a significant predictor of adverse cardiac events across diverse patient populations, including those with and without pre-existing heart disease.
  • It is observed in numerous medical conditions and can manifest as a congenital or acquired electrocardiogram (ECG) anomaly.
  • The prolonged QT interval is the hallmark symptom of long QT syndrome (LQTS).

Purpose:

  • To elucidate the clinical significance of the QT interval in electrocardiography.
  • To outline standardized measurement rules and address challenges in accurately assessing QT/QTc intervals.
  • To discuss the etiologies of QT interval prolongation, encompassing congenital and acquired forms of long QT syndrome, and to review management strategies.

Summary:

  • This review details the prognostic implications of QT interval prolongation in cardiology.
  • It covers the diagnostic criteria, measurement techniques, and common causes of prolonged QT intervals.
  • The paper also addresses the management of patients with QT prolongation and preventative measures for iatrogenic LQTS.

Impact:

  • Improved understanding of QT interval prolongation aids in risk stratification and patient management.
  • Accurate ECG interpretation can lead to earlier diagnosis and intervention for long QT syndrome.
  • Knowledge of iatrogenic causes facilitates the prevention of drug-induced QT prolongation and associated arrhythmias.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...